DIVISLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2019-04-01 2020-03-31 2020-05-30 INR Lakhs Yearly Single segment Pharmaceuticals 2020-01-01 2020-03-31 Audited Standalone 13762400000.00 765200000.00 14527600000.00 5422400000.00 0.00 -323600000.00 1697300000.00 4000000.00 495400000.00 2479900000.00 9775400000.00 4752200000.00 0.00 4752200000.00 530900000.00 303300000.00 834200000.00 0.00 3918000000.00 0.00 0.00 0.00 0.00 3918000000.00 -59500000.00 3858500000.00 0.00 0.00 530900000.00 2 14.76 14.76 0.00 0.00 14.76 14.76 NOTES: n1.tThe above Statement of standalone financial results for the quarter and year ended 31st, March 2020, Statement of standalone assets and liabilities and Statement of standalone cash flows as at and for the year ended March 31, 2020 ('Standalone Statements') are prepared in accordance with Indian Accounting Standards ('lnd AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on June 6, 2020. The same also were audited by the Auditors of the Company and their report contains no qualification. n2.tThe Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108. n3.tThe Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. n4.tCurrent Tax Expense includes adjustment of tax reversals of earlier years amounting to Rs.3370 lakhs. n5.tThe Company considered the uncertainty relating to the COVID-19 pandemic in assessing the recoverability of its inventories, receivables and investments. As the company is into essential manufacturing service which is exempt from lockdown restrictions, there has been minimal impact in its operations and its supply chain. In this regard, the Company has considered internal and external information while finalizing various estimates in relation to its financial statements upto the date of approval by the Board of Directors and has not identified any material impact on the carrying value of assets, liabilities or provisions. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic conditions. n6.tThe Ministry of Corporate Affairs (MCA), on 30th March, 2019, notified lndAS 116 Leases as part of the Companies (Indian Accounting Standards) Amendment Rules, 2019. The new standard is effective for accounting periods beginning on or after 1st April, 2019. The adoption of the standard did not have any material impact to the financial results of the Company. n7.t*Figures for the quarter ended 31.03.2020 and corresponding quarter ended 31.03.2019 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years. n8.tThe Board of Directors of the company has declared and paid an interim dividend of Rs. 16 per share of face value Rs.2 each i.e., 800% for the financial year 2019-20. No final dividend is recommended. The total dividend payout for the current year amounted to Rs. 51206 lakhs including dividend tax. n9.tDetails of forex gain/loss are given below: . in lakhs) ntQuarter endedtYear Ended nt31.03.2020t31.12.2019t31.03.2019t31.03.2020t31.03.2019 nt(Audited)*t(Unaudited)t(Audited)*t(Audited)t(Audited) nForex gain/ (loss) t5716t1790t(743)t8204t3092 n Forex gain has been included in Other Income and loss has been included in Other Expenses. n10.tFigures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year’s classification. Single segment 2019-04-01 2020-03-31 Audited Standalone 53105700000.00 1898600000.00 55004300000.00 21826600000.00 0.00 -941000000.00 6083600000.00 60600000.00 1859500000.00 7982100000.00 36871400000.00 18132900000.00 0.00 18132900000.00 3877900000.00 527900000.00 4405800000.00 0.00 13727100000.00 0.00 0.00 0.00 0.00 13727100000.00 -52100000.00 13675000000.00 0.00 0.00 530900000.00 2 72636000000.00 51.71 51.71 0.00 0.00 51.71 51.71 Other Expenses 2479900000.00 Other Expenses 7982100000.00